ALX4

Across TCGA pan-cancer cohorts, ALX4 Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ALX4 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ALX4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ALX4 expression acts as an unfavorable survival marker.

COAD, LUAD, and SARC are the cancer types where ALX4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	OS	Median	IV	0.089	0.649	.005	18	view →
LUAD	OS	Median	III,IV	0.237	0.687	.002	18	view →
SARC	OS	Median	All	0.032	0.861	<.001	12	view →
LIHC	DFS	Median	All	0.094	0.555	.005	12	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
BRCA	DFS	Median	All	0.824	0.949	.018	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ALX4–COAD (OS)

Open the COAD breakdown →